The Future of PTSD Treatment: Sorting the Promising From the Premature

Summary

New PTSD treatments arrive looking finished. One fact covers all of them: not a single treatment discussed in this essay is FDA-approved for PTSD. MDMA-assisted therapy has the strongest randomized evidence here and was rejected by the FDA in 2024. Every published psilocybin result in PTSD comes from 34 people across two studies with no comparison group. Ketamine is not approved for any psychiatric condition, and the US guideline suggests against it for PTSD. Four device authorizations name PTSD, and none is a full approval. Several serious, well-funded attempts have already failed outright — which is what a working test looks like. Meanwhile the treatments in the previous essay are available this month.

Zoom

Why This Matters Now

Fresh concrete looks finished the moment it is smoothed. Flat, even, done. Nobody parks a loaded truck on it that afternoon. The crew pours a few extra cylinders from the same batch, and a lab crushes one at seven days and another at twenty-eight. The only way to know what a slab will hold is to break a piece of it later, on purpose.

New PTSD treatments arrive looking finished. A striking number. A press release. Some of them will hold. Some are still setting. A few have already been crushed, and they failed.

And the sidewalk you are standing on has been carrying weight for years.

Start Here: The Treatments That Already Work

Before any of the frontier, here is the part that matters most.

As of August 2026, three talk therapies carry the strongest possible rating in the US guideline for PTSD: Cognitive Processing Therapy, EMDR, and Prolonged Exposure. Three more are named as good options, and one of those runs five sessions with no homework. The guideline says to start with therapy rather than medicine when you can, and it gives its strongest rating to delivering that therapy over secure video. [1]

Sertraline and paroxetine are the only medicines the FDA has approved for PTSD.

Two-week versions of the leading therapies did as well as the weekly ones, and far more people finished them. [1]

All of this is available now. Nothing below is a reason to wait.

Now the frontier. One fact covers everything that follows. Not one of the treatments in the rest of this article is FDA-approved for PTSD. Not one.

How a Treatment Earns Trust

A slab nobody has tested is a guess. So the lab breaks a cylinder on purpose, then another later. New treatments earn trust the same way, and three things do the testing.

A comparison group. The people who get something else — a dummy version, usual care, or a fake procedure. Without them you cannot tell how much of the change came from the treatment rather than from time, attention, and hope.

Blinding. Nobody involved knows who got what. When people can tell, because a drug has obvious effects, the blinding has failed.

Time and repeating. A benefit measured once at one month says nothing about a year. And until someone else runs the study again and gets the same answer, one result is one result.

One habit is worth building, because it decodes most headlines. “Within-group change” is how much a treated group changed from start to finish. “Between-group difference” is how much better that group did than the comparison. The bigger first number usually makes the headline. Only the second tells you what the treatment did.

MDMA-Assisted Therapy: The Furthest Along, and Stalled

MDMA is a Schedule I drug. It is federally illegal and not approved for PTSD.

It also has the strongest randomized evidence on this list. Two completed Phase 3 trials used raters who did not know who got what. In the first, 28 of 42 people in the drug group no longer met criteria for PTSD, against 12 of 37 in the comparison group. [2] In the second, it was 37 of 52 against 20 of 42. [3]

Read those alongside one more fact. Both groups also received about forty hours of intensive therapy, and the placebo group improved a great deal on its own. In the second trial the drug group improved about 24 points on the standard PTSD interview and the placebo group about 15. [3] Only the 9-point gap describes the drug. Roughly 60% of the total improvement happened in the placebo arm.

The blinding failed. In the only survey of its kind, 49 of 52 people in the drug group correctly guessed they had received it — which is what you would expect from a drug with unmistakable effects. A journal also withdrew three widely quoted pooled analyses in August 2024, citing unethical conduct at one site. [4][5] Any figure from those three papers is no longer citable, which means the usable evidence base is the two Phase 3 trials and nothing else.

On June 4, 2024, an FDA advisory committee voted 2 to 9 and 1 to 10 against, and an independent review group rated the evidence “insufficient.” The FDA then sent a Complete Response Letter — its formal “not yet” — dated August 8, 2024. [6] As of August 5, 2026, no new Phase 3 trial had been registered.

Two opposite errors are easy to make here, and both are wrong. Positive Phase 3 results do not mean approval is coming. And the rejection does not prove the treatment does not work — the FDA raised questions about how the trials were run, not a finding that the drug is useless.

Psilocybin: What Actually Exists

Psilocybin is Schedule I as well: federally illegal, and not approved for PTSD or anything else.

Add up every person with PTSD who has taken psilocybin in a published study. The total is thirty-four, across two studies. Neither had a comparison group, and everyone knew what they were getting. Randomized psilocybin trials in PTSD that have reported results: zero. [7]

The number you have probably seen is “75% remission.” That is 9 of 12 veterans, measured once, a month after their second session, with nobody to compare them to. [7] A very large effect size gets quoted alongside it. That number describes how much those nine people changed — not how much the treatment changed them. For scale: in the MDMA trial above, the placebo-plus-therapy group improved by about 15 points with no active drug at all. [3] An open study can flag a safety problem early. It cannot show that a treatment works.

The first properly sized randomized trial plans to enroll 300 people. As of August 5, 2026 it had enrolled nobody, and results are expected in November 2028.

Evidence in depression is a reason to run the study in PTSD. It is not a substitute for running it.

Ketamine: Approved, but Not for This

In the FDA’s own words, from October 2023: ketamine is not approved for the treatment of any psychiatric disorder. [10] Ketamine is approved as an anesthetic. Esketamine is approved for depression that has not responded to other treatment, and PTSD appears nowhere in its label. The US guideline does not just call the evidence thin — it suggests against ketamine for PTSD. [1]

The largest and most careful trial enrolled 158 veterans and service members. PTSD symptoms did not improve more than placebo. Depression did. [8] When the trials were pooled and corrected for study bias, the PTSD benefit was no longer distinguishable from zero. [9] “Ketamine-assisted psychotherapy” has never been shown to beat ketamine alone.

The version reaching the most people has the least oversight. The FDA warns that at-home use adds risk, and has described a 2023 case of a patient whose breathing slowed dangerously after taking compounded oral ketamine at home for PTSD. [10]

Devices and Procedures

Four FDA device authorizations name PTSD. None is a full approval, and none rests on a published trial that beat a convincing fake. One device’s pivotal trial missed its main target; another was cleared on a single-arm study of 66 people.

Four terms get confused constantly, and the difference between them is most of the story.

• FDA approved. The FDA reviewed evidence that the product works for this condition.
• FDA cleared. A device is close enough to something already on the market to be sold. That is not a finding that it works.
• State licensed. A state allows supervised use. It is still federally illegal.
• Legal somewhere else. Another country made an exception to its own rules.

Brain stimulation is not established for PTSD. The US guideline calls the evidence insufficient for several of these approaches and suggests against two more. [1] In trials using a convincing fake, they have not reliably beaten it, and in one study the fake did better.

A nerve-block procedure is the partial exception. A stellate ganglion block is a numbing injection into a nerve bundle in the neck. In the best-run trial, 113 service members received either the real injection or a sham, and the real one worked better by about 6 points on an 80-point scale over eight weeks, in people with mild to moderate symptoms. [11] An earlier randomized trial of the same procedure found no difference. [12] Nobody has tested whether the benefit lasts beyond two months.

A state program or legal access abroad is not the same as vetting. Oregon’s and Colorado’s psilocybin programs require no diagnosis, no prescription, and no licensed healthcare provider, and psilocybin remains Schedule I. Australia lets certain psychiatrists supply an unapproved product, and its own regulator says plainly that these substances have not been assessed for safety, quality, or effectiveness. [27] No country has approved psilocybin or MDMA for PTSD.

What Already Failed, and Why That Is Useful

Several serious, well-funded attempts have failed in the past two years.

A medicine added to sertraline had one positive Phase 3 trial and one that clearly failed; a committee voted 1 to 10 against it, and the FDA sent a rejection letter on September 20, 2025. A drug aimed at a brain enzyme failed twice in independent trials even though imaging confirmed it reached its target. [13][14] Two Phase 3 trials of a sublingual compound stopped early for lack of benefit. And risperidone added to an antidepressant was negative in 296 veterans — a well-run trial that closed off a common off-label practice. [15]

Not all the news is discouraging. One new compound has a published randomized Phase 2 result and a Phase 3 trial that began recruiting on April 2, 2026. One detail is worth noticing: its published range was a 90% interval rather than the usual 95%, which is a slightly lower bar for calling a result positive.

The same caution applies to the prediction tools now being marketed alongside these treatments. An attempt to replicate brain-based “biotypes” that would sort people after trauma did not hold up. [16][17] In one external-validation study, a brief symptom questionnaire out-predicted the elaborate models at every time point. [18]

Every one of those failures is a cylinder crushed on schedule. That is not a sign the field is broken. That is what a working test looks like.

Prevention: The One Clear Answer

Making everyone tell the story right after a disaster does not prevent PTSD. A Cochrane review found no benefit, and in one trial the people who did it were worse off a year later. Its conclusion was that compulsory debriefing of trauma victims should stop. [19]

What works better is simple. Check in a few weeks later, and treat the people who are struggling. Across 61 randomized trials, people who were not screened for symptoms got no meaningful benefit from early treatment, while people reporting symptoms clearly did. [20] Preventive propranolol, a pill given right after the event, did not work. [21]

The best-supported step here costs almost nothing. ICU diaries — a written record kept for patients who were critically ill — lowered the odds of later PTSD across seven studies and about a thousand patients. [22][23]

Myths vs Facts

Risks, Limitations, and Uncertainties

The honest summary is short. A few of these treatments have serious randomized evidence. Most have almost none. Several have already failed. None is approved for PTSD.

Where the uncertainty sits matters. For MDMA-assisted therapy, the randomized between-group effects are real and so are the methodological problems, and neither cancels the other. Nobody knows how much of the benefit belongs to the drug versus the forty hours of therapy delivered alongside it, and near-total unblinding means expectation cannot be separated out. Durability past about four months is untested.

For psilocybin, there is simply not enough evidence to have an opinion about efficacy yet. For ketamine, the PTSD-specific question looks closer to negative than to unproven. For devices, the pivotal data are often unpublished, so claims rest on press releases rather than trials.

There are real harms to weigh, not just an absence of benefit. About a third of people who reported a badly distressing psychedelic experience later met criteria for PTSD. [24] Ibogaine, sometimes promoted for trauma, can prolong the heart’s QT interval and trigger fatal arrhythmias, with cardiac arrest reported. [25][26] St. John’s wort blocks the same enzyme older antidepressants act on and can set off a dangerous reaction with medicines many people with PTSD already take.

One risk lands on you before anyone else. In a clinical trial you may be asked to stop a medicine that is helping, and there may be no guarantee you can restart it. In one earlier MDMA trial, a participant reported inappropriate touching by two therapists during a session — a reminder that these treatments involve long sessions in an altered state, and that the rules around them are worth seeing in writing.

Cost is its own problem. Most of this is not covered by insurance, and stellate ganglion blocks run roughly $1,100 to $3,200 out of pocket.

What This Means for You

Six questions cover most of what you need to evaluate any new treatment.

1. Who paid for the study.
2. Whether the person scoring the results knew which group you were in.
3. Whether there was a comparison group, and whether it was a real one.
4. Whether the headline number is how much people changed, or how much better the treatment did than the comparison.
5. How long the benefit was measured.
6. Whether anyone else has repeated it.

Two more if you are considering joining a study. Ask whether you would have to stop a medicine that is helping you, and what happens if you get worse. Then ask to see, in writing, the rules about physical contact, recording, who else will be in the room, and who to contact if something goes wrong.

The steadiest advice: not before you have had a real try at something that already works. If you still want something new after that, do it inside a system that is accountable to you.

Questions to Ask Your Prescriber

• Have I had a fair trial of the treatments that are already proven?
• Is this approved by the FDA for PTSD, or cleared, or neither?
• What did the comparison group in that study receive?
• Would I have to stop anything I am currently taking, and could I restart it?
• What happens if I get worse during this?
• Do any of my current medicines interact with it?
• What will this cost me, and is any of it covered?

Frequently Asked Questions

Q: Is MDMA-assisted therapy approved yet?

No. The FDA rejected it in 2024 and asked for another Phase 3 trial. That trial had not been registered as of August 5, 2026. [6]

Q: Has psilocybin been proven for PTSD?

No. Thirty-four people, two studies, no comparison group, and zero randomized results. [7]

Q: A clinic says ketamine treats PTSD. Is that right?

Ketamine is not FDA-approved for any psychiatric condition, and neither is esketamine. In the largest careful trial, depression improved and PTSD did not. [8][10]

Q: A device near me is “FDA cleared.” What does that mean?

It means close enough to something already sold to be marketed. It is not a finding that it treats PTSD.

Q: Should I join a clinical trial?

Ask your clinician whether a study is right for you, whether you would have to stop a medicine that is helping, and whether you could restart it. Trials are a reasonable choice for some people — going in with those answers is what makes it an informed one.

Q: Some of this will change. How do I check?

Watch three things. Has the FDA approved it for PTSD? Has a randomized trial with a real comparison group reported results? Has someone else repeated it? Your prescriber and the current VA/DoD guideline can tell you.

Q: Is a natural product a safer place to start?

Not automatically. “It grows in the ground” is not a safety claim, and several plant-derived products carry serious interaction and cardiac risks. [25][26]

Key Takeaways

• Not one treatment in this essay is FDA-approved for PTSD.
• MDMA-assisted therapy has the strongest randomized evidence here and was rejected by the FDA in August 2024; three widely quoted pooled analyses were retracted. [2][3][4][5][6]
• Everything published on psilocybin for PTSD comes from 34 people in two open-label studies with no comparison group. [7]
• Ketamine is not approved for any psychiatric condition, and the guideline suggests against it for PTSD. [1][8][9]
• Cognitive Processing Therapy, EMDR, Prolonged Exposure, and two approved medicines are available this month. Start there.

If You Only Remember One Thing…

Nothing on the frontier is a reason to delay a treatment that already works.

Conclusion

The crew keeps crushing cylinders on schedule, and the sidewalk you are standing on keeps carrying weight. Some of what is being tested now will hold, and some of it will not, and the only way anyone will know is the slow, unglamorous work of breaking a piece of it on purpose. In the meantime, the treatments in the previous essay in this series are available, proven, and waiting.

This article is for education only — it is not medical advice. The regulatory facts here are current as of August 5, 2026 and may change. Talk with your prescriber before you:

• Start or stop any medication
• Enroll in a clinical trial
• Try any product marketed for PTSD, including natural or plant-derived ones
• Make a major health decision

Related reading

• How PTSD Is Treated Today: What Works, and What Order to Try It In
• The Many Faces of PTSD: Why It Almost Never Looks Like the Movies
• Psilocybin: A Once-Sacred Mushroom Making Its Way Into Modern Medicine

References

1. US Department of Veterans Affairs, US Department of Defense. VA/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Version 4.0. June 2023. Recommendations 7, 8, 9, 18, 24, 25, 29. https://www.healthquality.va.gov/guidelines/MH/ptsd/. Accessed August 5, 2026.

2. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. doi:10.1038/s41591-021-01336-3. PMID:33972795.

3. Mitchell JM, Ot’alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. doi:10.1038/s41591-023-02565-4. PMID:37709999.

4. Jerome L, Feduccia AA, Wang JB, et al. Retraction note: long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl). 2024;241(11):2407. doi:10.1007/s00213-024-06665-y. PMID:39126500.

5. Feduccia AA, Jerome L, Mithoefer MC, et al. Retraction note: discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy. Psychopharmacology (Berl). 2024;241(11):2403. doi:10.1007/s00213-024-06671-0. PMID:39126502.

6. US Food and Drug Administration. Complete Response Letter for midomafetamine capsules (NDA 215455), dated August 8, 2024; released September 4, 2025. Psychopharmacologic Drugs Advisory Committee meeting, June 4, 2024 (votes 2–9 and 1–10). Institute for Clinical and Economic Review final evidence report, June 27, 2024.

7. Armstrong SB, Levin AW, Sepeda ND, et al. Safety, feasibility, and preliminary clinical outcomes of psilocybin-assisted therapy for veterans with severe, treatment-resistant PTSD: an open-label pilot clinical trial. Commun Med (Lond). 2026;6(1):411. doi:10.1038/s43856-026-01767-4. PMID:42533157. With open-label study NCT05312151 and planned randomized trial NCT07570654.

8. Abdallah CG, Roache JD, Gueorguieva R, et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology. 2022;47(8):1574-1581. doi:10.1038/s41386-022-01266-9. PMID:35046508.

9. Borgogna NC, Owen T, Vaughn J, et al. So how special is special K? A systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol. 2024;15(1):2299124. doi:10.1080/20008066.2023.2299124. PMID:38224070.

10. US Food and Drug Administration. FDA warns patients and health care providers about potential risks associated with compounded ketamine products. October 10, 2023.

11. Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of stellate ganglion block treatment on posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Psychiatry. 2020;77(2):130-138. doi:10.1001/jamapsychiatry.2019.3474. PMID:31693083. Corrected record: errata PMID:31895456 and PMID:32609314.

12. Hanling SR, Hickey A, Lesnik I, et al. Stellate ganglion block for the treatment of posttraumatic stress disorder: a randomized, double-blind, controlled trial. Reg Anesth Pain Med. 2016;41(4):494-500. doi:10.1097/AAP.0000000000000402. PMID:27187898.

13. Mayo LM, Gauffin E, Petrie GN, et al. The efficacy of elevating anandamide via inhibition of fatty acid amide hydrolase (FAAH) combined with internet-delivered cognitive behavioral therapy in the treatment of post-traumatic stress disorder: a randomized, placebo-controlled clinical trial. Neuropsychopharmacology. 2025;50(10):1564-1572. doi:10.1038/s41386-025-02128-w. PMID:40382500.

14. Tansey R, Perini I, Petrie GN, et al. Functional neuroimaging of fatty acid amide hydrolase inhibition in posttraumatic stress disorder: a randomized clinical trial. Transl Psychiatry. 2026;16(1). doi:10.1038/s41398-026-03864-3. PMID:41651806.

15. Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA. 2011;306(5):493-502. doi:10.1001/jama.2011.1080. PMID:21813427.

16. Ben-Zion Z, Spiller TR, Keynan JN, et al. Evaluating the evidence for brain-based biotypes of psychiatric vulnerability in the acute aftermath of trauma. Am J Psychiatry. 2023;180(2):146-154. doi:10.1176/appi.ajp.20220271. PMID:36628514.

17. Siegel CE, Laska EM, Lin Z, et al. Utilization of machine learning for identifying symptom severity military-related PTSD subtypes and their biological correlates. Transl Psychiatry. 2021;11(1):227. doi:10.1038/s41398-021-01324-8. PMID:33879773.

18. Chu X, Dai X, Jiang X, et al. Development and validation of machine learning models to predict PTSD at multiple time points in hospitalized trauma patients. J Affect Disord. 2026;399:121096. doi:10.1016/j.jad.2025.121096. PMID:41478384.

19. Rose S, Bisson J, Churchill R, et al. Psychological debriefing for preventing post traumatic stress disorder (PTSD). Cochrane Database Syst Rev. 2002;(2):CD000560. doi:10.1002/14651858.CD000560. PMID:12076399.

20. Roberts NP, Kitchiner NJ, Kenardy J, et al. Early psychological intervention following recent trauma: a systematic review and meta-analysis. Eur J Psychotraumatol. 2019;10(1):1695486. doi:10.1080/20008198.2019.1695486. PMID:31853332.

21. Argolo FC, Cavalcanti-Ribeiro P, Netto LR, et al. Prevention of posttraumatic stress disorder with propranolol: a meta-analytic review. J Psychosom Res. 2015;79(2):89-93. doi:10.1016/j.jpsychores.2015.04.006. PMID:25972056.

22. Huang W, Gao Y, Zhou L, et al. Effects of ICU diaries on psychological disorders and sleep quality in critically ill patients and their family members: a systematic review and meta-analysis. Sleep Med. 2024;122:84-91. doi:10.1016/j.sleep.2024.08.002. PMID:39137664.

23. Cai Y, Ren X, Ding C. Impacts of non-pharmacological interventions on post-intensive care syndrome: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials. Intensive Crit Care Nurs. 2026;93:104326. doi:10.1016/j.iccn.2025.104326. PMID:41481952.

24. Evens R, Uyar A, Gosslau E, et al. Post-traumatic stress disorder symptoms following psychedelic use: a naturalistic survey study. Psychol Med. 2026;56:e88. doi:10.1017/S0033291726103754. PMID:41919323.

25. Brunt TM. Rare but relevant: ibogaine and cardiovascular complications — prolonged QT interval and ventricular arrhythmias. Addiction. 2026;121(6):1616-1621. doi:10.1111/add.70319. PMID:41560340.

26. Mestre D, Paula A, Gil FP, et al. Multiple episodes of cardiac arrest induced by treatment with ibogaine: a case report. Cureus. 2024;16(6):e63487. doi:10.7759/cureus.63487. PMID:39081435.

27. US Food and Drug Administration. Psychedelic Drugs: Considerations for Clinical Investigations. Final guidance, July 2026 (docket FDA-2023-D-1987). With 21 CFR 1308.11 and 1308.13; Oregon Health Authority Psilocybin Services; Colorado Natural Medicine Division; Therapeutic Goods Administration (Australia) unapproved therapeutic goods and Authorised Prescriber pages. All retrieved August 5, 2026.

If you or someone you know is in crisis

• Call 911 or go to your nearest emergency room for any life-threatening emergency.
• 988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.
• Crisis Text Line — text HOME to 741741.
• The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.
• National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.
• National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.
• Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.
• San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).
• Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.
• California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.
• NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.